Cargando…

Carbapenem-Sparing Strategies for ESBL Producers: When and How

Extended spectrum β-lactamase (ESBL)-producing bacteria are prevalent worldwide and correlated with hospital infections, but they have been evolving as an increasing cause of community acquired infections. The spread of ESBL constitutes a major threat for public health, and infections with ESBL-prod...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karaiskos, Ilias, Giamarellou, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167803/ https://www.ncbi.nlm.nih.gov/pubmed/32033322 http://dx.doi.org/10.3390/antibiotics9020061

Ejemplares similares

Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches
por: Karaiskos, Ilias, et al.
Publicado: (2014)

Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients
por: Giamarellou, Helen, et al.
Publicado: (2022)

Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance
por: Galani, Irene, et al.
Publicado: (2019)

Correction to: Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance
por: Galani, Irene, et al.
Publicado: (2019)

Antimicrobial Stewardship in the Hospital Setting: A Narrative Review
por: Giamarellou, Helen, et al.
Publicado: (2023)

Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
por: Fukuchi, Takahiko, et al.
Publicado: (2016)

Carbapenem-Resistant and ESBL-Producing Enterobacterales Emerging in Central Texas
por: Parker, Jennifer K, et al.
Publicado: (2023)

To Use, or Not to Use Carbapenem When Extended-spectrum β-lactamase (ESBL)-producing Bacteria Are Isolated from Sputum Cultures, That Is the Question
por: Miki, Makoto
Publicado: (2017)

Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019
por: Galani, Irene, et al.
Publicado: (2020)

1153. ESBL Producing E. coli Urinary Tract Infections in Children: Is Carbapenem Always Necessary?
por: del Carmen, Ruiz Cabrales Diva, et al.
Publicado: (2021)

647. Cefepime Versus Carbapenems for the Treatment of ESBL-producing Enterobacterales among Non-blood Isolates
por: Garcia, Brandon, et al.
Publicado: (2022)

The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How
por: Karaiskos, Ilias, et al.
Publicado: (2019)

1452. Is Carbapenem-Sparing Therapy as Effective as Carbapenems Against Extended-Spectrum β-Lactamase Producing Enterobacteriaceae in UTI?
por: Hyun, Jonghoon, et al.
Publicado: (2019)

Prevalence of ESBL-Producing Enterobacter Species Resistant to Carbapenems in Iran: A Systematic Review and Meta-Analysis
por: Khademi, Farzad, et al.
Publicado: (2022)

Large vessel vasculitis in a patient with acute Q-fever: A case report
por: Baziaka, Fotini, et al.
Publicado: (2014)

1508. Carbapenem vs. Non-carbapenem as Empiric Regimens for Bacteremia Caused by ESBL Producing Escherichia coli and Klebsiella pneumoniae in Children: Preliminary Study
por: Park, Saera, et al.
Publicado: (2019)

Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings
por: Readman, J B, et al.
Publicado: (2023)

479 Clinical outcomes in patients with extended-spectrum-beta-lactamase-producing (ESBL) Enterobacteriaceae bloodstream infections (ESB) treated with carbapenems (CP) and non-carbapenems (NC)
por: Chin, Judy, et al.
Publicado: (2014)

838. Drivers of empiric carbapenem use: How important is history of extended-spectrum beta-lactamase (ESBL) infection?
por: Stone, Tyler J, et al.
Publicado: (2020)

Distribution of carbapenem resistant Acinetobacter Baumannii and Pseudomonas aeruginosa and ESBL-producing organisms colonization among intensive care patients
por: Santanirand, P, et al.
Publicado: (2011)

2442. Outcomes in ESBL Bacteremia Empirically Treated With Piperacillin/Tazobactam or Carbapenems
por: John, Reeba, et al.
Publicado: (2018)

Temocillin: Applications in Antimicrobial Stewardship as a Potential Carbapenem-Sparing Antibiotic
por: Lupia, Tommaso, et al.
Publicado: (2022)

1199. Effectiveness of Non-carbapenem vs Carbapenems Empiric Therapy for Extended-Spectrum β-Lactamase (ESBL)-producing Enterobacterales (PE) Infections in Non-ICU patients: A Real-world Investigation in a Hospital with High-prevalence of ESBL-PE
por: Kang, Amy Y, et al.
Publicado: (2023)

Re-evaluation of cefepime or piperacillin/tazobactam to decrease use of carbapenems in ESBL-producing Enterobacterales urinary tract infections (REDUCE-UTI)
por: Branton, Alexander C, et al.
Publicado: (2023)

Extended-Spectrum β-Lactamases (ESBL) Producing Bacteria in Animals
por: Tseng, Chien-Hao, et al.
Publicado: (2023)

ESBL Activity, MDR, and Carbapenem Resistance among Predominant Enterobacterales Isolated in 2019
por: Bandy, Altaf, et al.
Publicado: (2021)

Moxalactam is not more active on extended spectrum β-lactamase (ESBL) producing bacteria than on non-ESBL producers
por: Singh, Bhoj R
Publicado: (2018)

Overview of ESBL-producing Enterobacteriaceae from a Nordic perspective
por: Brolund, Alma
Publicado: (2014)

1576. Re-Evaluation of cefepime or piperacillin-tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales BloodStream Infections (REDUCE-BSI)
por: Vu, Catherine H, et al.
Publicado: (2020)

1257. Re-Evaluation of Cefepime or Piperacillin-Tazobactam to Decrease Use of Carbapenems in ESBL-Producing Enterobacterales Urinary Tract Infections (REDUCE-UTI)
por: Branton, Alexander C, et al.
Publicado: (2021)

Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016
por: Galani, Irene, et al.
Publicado: (2018)

Oral fosfomycin for the treatment of chronic bacterial prostatitis
por: Karaiskos, Ilias, et al.
Publicado: (2019)

Calculated parenteral initial treatment of bacterial infections: Infections with multi-resistant Gram-negative rods – ESBL producers, carbapenemase-producing Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii
por: Grabein, Béatrice, et al.
Publicado: (2020)

Treatment of Piperacillin-Tazobactam–Nonsusceptible/Ceftriaxone-Susceptible Infections With Carbapenem Versus Carbapenem-Sparing Antimicrobials
por: Cao, John, et al.
Publicado: (2023)

Characterization of qnrB-carrying plasmids from ESBL- and non-ESBL-producing Escherichia coli
por: Juraschek, Katharina, et al.
Publicado: (2022)

Prevalence of ESBL-producing Enterobacteriaceae in raw vegetables
por: Reuland, E. A., et al.
Publicado: (2014)

The emergence of carbapenem resistance in ESBL-producing Escherirchia coli O25B-ST131 strain from community acquired infection in Kuwait
por: Dashti, AA, et al.
Publicado: (2011)

ESBL-Producing, Carbapenem- and Ciprofloxacin-Resistant Escherichia coli in Belgian and Dutch Broiler and Pig Farms: A Cross-Sectional and Cross-Border Study
por: De Koster, Sien, et al.
Publicado: (2021)

Initial empirical antibiotics of non-carbapenems for ESBL-producing E. coli and K. pneumoniae bacteremia in children: a retrospective medical record review
por: Park, Saera, et al.
Publicado: (2022)

Travel-acquired ESBL-producing Enterobacteriaceae: impact of colonization at individual and community level
por: Woerther, Paul-Louis, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ne5anvbpaqdnb0dio3to5pp2i7